Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib +/- 5-azacytidine in FLT3-mutated AML
NCT02829840Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ponatinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 2016; status: withdrawn.
02
Drugs
ponatinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02829840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829840.